Brief: Grand Pharmaceutical's Global Innovative RDC Drug I-11 Obtained Implied Approval From NMPA
08/05/2023 11:40
May 8 (Reuters) - Grand Pharmaceutical Group Ltd
0512.HK :
* GLOBAL INNOVATIVE RDC DRUG OF GROUP ITM-11 OBTAINED
IMPLIED
APPROVAL FROM NMPA TO CONDUCT PHASE I CLINICAL STUDY
Source text for Eikon: ID:nHKS46k8kx
Further company coverage: 0512.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grand Pharmaceutical
See all newsBrief: Grand Pharmaceutical Group Declares No Interim Dividend Has Been Paid
Grand Pharmaceutical H1 revenue rises on nuclear medicine demand
Grand Pharma rises most in over a year as drug gets US FDA fast track designation
GPN01530-2 Granted Fast Track Designation By FDA
Brief: Grand Pharmaceutical Group Enters Huadong Medicine Supply Agreement